Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in operable breast cancer patients with hormone receptor-positive, HER2-negative - Summary - MDSpire
Advertisement
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in operable breast cancer patients with hormone receptor-positive, HER2-negative
To compare the long-term survival outcomes of patients with operable hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer at stage II and T3N1M0 receiving neoadjuvant chemotherapy (NACT) versus adjuvant chemotherapy (ACT).
Key Findings:
NACT group had significantly inferior 5-year overall survival (OS) at 87.4% compared to 91.8% in the ACT group (P<0.0001).
NACT group showed inferior breast cancer-specific survival (BCSS) at 89.3% versus 93.7% in the ACT group (P<0.0001).
Patients achieving objective response to NACT had higher risks of breast cancer-specific death (HR = 1.42, 95% CI: 1.17-1.73) and all-cause death (HR = 1.31, 95% CI: 1.10-1.57) compared to ACT.
Interpretation:
NACT is associated with worse long-term survival outcomes compared to ACT in operable HR+/HER2- breast cancer patients, indicating a need for caution in treatment selection based on these findings.
Limitations:
Retrospective nature of the study may introduce selection bias.
Data limited to a specific population from the SEER database.
Potential confounding factors affecting survival outcomes were not fully accounted for.
Conclusion:
In operable HR+/HER2- breast cancer at stage II and T3N1M0, NACT is linked to inferior OS and BCSS compared to ACT, suggesting careful consideration in treatment planning.
